relatlimab,nivolumab
bms
['relativity-047', 'melanoma', 'bristol']
 2022 updates:
at the #asco 2022, presented a subgroup analysis from the relativity-047 trial for opdualag for unresectable or metastatic #melanoma #patients. get more insights at: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry